PATH | VRL
Menu

Development and Preclinical Evaluation of Safety and Immunogenicity of an Oral ETEC Vaccine Containing Inactivated E. coli Bacteria Overexpressing Colonization Factors CFA/I, CS3, CS5 and CS6 Combined With a Hybrid LT/CT B Subunit Antigen, Administered Alone and Together With dmLT Adjuvant

This article, published in Vaccine, describes the development and preclinical testing of new oral vaccine against enterotoxigenic Escherichia coli (ETEC) administered alone and in combination with an adjuvant. The studies found that oral immunization with the vaccine candidate induced intestinal and serum antibody responses to all antigens, and these responses were further enhanced by dmLT, a nontoxic E. coli adjuvant. In addition, the vaccine, given both with and without dmLT, was stable and well tolerated.

Author: Holmgren J, Bourgeois L, Carlin N, et al.

Published: 2013

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Holmgren J, Bourgeois L, Carlin N, et al. Development and Preclinical Evaluation of Safety and Immunogenicity of an Oral ETEC Vaccine Containing Inactivated E. coli Bacteria Overexpressing Colonization Factors CFA/I, CS3, CS5 and CS6 Combined With a Hybrid LT/CT B Subunit Antigen, Administered Alone and Together With dmLT Adjuvant. Vaccine. 2013;31(20):2457-2464.

Resource types: Peer-reviewed journal

Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Global